CDKL5 Deficiency Disorder Treatment Market: By Therapies (First Line Therapy (Antiepileptic Drugs and Anticonvulsant Drugs), Second line Therapies), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

CDKL5 Deficiency Disorder Treatment Market was valued at USD 10.5 million in 2022 and is poised to grow at a CAGR of  8.5% from 2023 to 2029. According to the National Institutes of Health, CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Increased awareness of such treatment and availability of first-line drugs in the market such as antileptic and anticonvulsant drugs which help to the patient for an easy cure, the growing incidence of CDKL across the world, increasing research and development drive the market, rare patient, and fewer clinical trials on CDKL5 drugs are the major restraints in the market. Frequency. CDKL5 deficiency disorder appears to be a rare condition with an incidence of 1 in 40,000 to 60,000 newborns. About 90 percent of those diagnosed with CDKL5 deficiency disorder are girls, making it one of the most common forms of genetic epilepsy. The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development.  

CDKL5 Deficiency Disorder Treatment Market Key Developments:

In March 2022, Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. ZTALMY® (ganaxolone) is an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older, ZTALMY® is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptor.

CDKL5 Deficiency Disorder Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.5%

Largest Market

North America

Fastest Growing Market

North America
CDKL5 Deficiency Disorder Treatment Market Dynamics

The increasing prevalence of epileptic genetic disorders among children across the world is the major market driver in the CDKL5 Deficiency Disorder Treatment Market during the forecast period. CDKL5 deficiency disorder affects newborns, with impaired gross motor skills (such as walking, and running) also impaired fine motor skills and language and social skills. The treatment for such disease is rare, an increase in research and development of new drugs leads to growth in the market. Hence, this will drive the global market growth at a significant rate.

CDKL5 Deficiency Disorder Treatment Market Segmentation

By Therapies
  • First Line Therapy
  • Second line Therapies
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The CDKL5 deficiency disorder treatment market size was valued at USD 10.5 million in 2022, growing at an 8.5% CAGR from 2023 to 2029.

The leading players in the CDKL5 Deficiency Disorder Treatment Market are Marinus Pharmaceuticals, Takeda, Ovid Therapeutics, Zogenix, PTC Therapeutics, REGENXBIO, and Long Board Pharmaceuticals

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast presented from 2023 – 2029.

Key Features of the Reports

  • The CDKL5 deficiency disorder treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
1.Executive Summary
2.Global CDKL5 Deficiency Disorder Treatment Market Introduction 
2.1.Global CDKL5 Deficiency Disorder Treatment Market  - Taxonomy
2.2.Global CDKL5 Deficiency Disorder Treatment Market  - Definitions
2.2.1. By Therapies
2.2.2. By Distribution Channel
2.2.3. By Region
3.Global CDKL5 Deficiency Disorder Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global CDKL5 Deficiency Disorder Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global CDKL5 Deficiency Disorder Treatment Market  By Therapies, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. First Line Therapy
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Second line Therapies
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global CDKL5 Deficiency Disorder Treatment Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Hospital Pharmacy
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacy
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacy
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global CDKL5 Deficiency Disorder Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America CDKL5 Deficiency Disorder Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Therapies Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.First Line Therapy
8.1.2.Second line Therapies
8.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospital Pharmacy
8.2.2.Retail Pharmacy
8.2.3.Online Pharmacy
8.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe CDKL5 Deficiency Disorder Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Therapies Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.First Line Therapy
9.1.2.Second line Therapies
9.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital Pharmacy
9.2.2.Retail Pharmacy
9.2.3.Online Pharmacy
9.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
10.Asia Pacific (APAC) CDKL5 Deficiency Disorder Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Therapies Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.First Line Therapy
10.1.2.Second line Therapies
10.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital Pharmacy
10.2.2.Retail Pharmacy
10.2.3.Online Pharmacy
10.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) CDKL5 Deficiency Disorder Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Therapies Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.First Line Therapy
11.1.2.Second line Therapies
11.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital Pharmacy
11.2.2.Retail Pharmacy
11.2.3.Online Pharmacy
11.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America CDKL5 Deficiency Disorder Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Therapies Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.First Line Therapy
12.1.2.Second line Therapies
12.2.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital Pharmacy
12.2.2.Retail Pharmacy
12.2.3.Online Pharmacy
12.3.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Marinus Pharmaceuticals
13.2.2.Takeda
13.2.3.Ovid Therapeutics
13.2.4.Zogenix
13.2.5.PTC Therapeutics
13.2.6.REGENXBIO
13.2.7.Long Board Pharmaceuticals
14. Research Methodology 
15. Appendix and Abbreviations 
  • Marinus Pharmaceuticals
  • Takeda
  • Ovid Therapeutics
  • Zogenix
  • PTC Therapeutics
  • REGENXBIO
  • Long Board Pharmaceuticals

Adjacent Markets